Albumin Excipient Market Report 2025

The albumin excipient market size has grown strongly in recent years. It will grow from $4.85 billion in 2024 to $5.2 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to biopharmaceutical industry growth, increased adoption of biologics, risen prevalence of chronic diseases, clinical advancements and drug innovation, increased focus on drug delivery.

The albumin excipient market size is expected to see strong growth in the next few years. It will grow to $6.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to continued biopharmaceutical expansion, growing biologics pipeline, rising geriatric population, global vaccination initiatives, increasing drug development investments. Major trends in the forecast period include biodegradable and biocompatible properties, collaborations and partnerships in research, regulatory compliance and quality standards, application in cell therapy, customization and tailored solutions.

The increasing prevalence of chronic diseases is expected to drive the growth of the albumin excipient market in the future. Chronic diseases are illnesses that persist for three months or longer and can worsen over time. Albumin, the most abundant circulating protein in plasma, serves as a blood volumizer and a versatile protein carrier, aiding in drug targeting and enhancing the pharmacokinetic profile of peptide or protein-based medications used to treat various conditions, including cancer and diabetes. For instance, in February 2024, the World Health Organization, a United Nations agency based in Switzerland, projected that more than 35 million new cancer cases will occur by 2050, representing a 77% increase from an estimated 20 million cases in 2022. Thus, the rising prevalence of chronic diseases is a significant factor propelling the growth of the albumin excipient market.

The increase in healthcare expenditures is expected to drive the growth of the albumin excipient market in the future. Health expenditures encompass all costs related to delivering health services, family planning initiatives, nutrition programs, and emergency health assistance. Rising healthcare spending positively impacts the albumin excipient market by providing increased financial support for the development and use of advanced albumin-based formulations in pharmaceuticals and biopharmaceuticals. For example, the Canadian Institute for Health Information, a non-profit organization based in Canada, reported in November 2023 that total health expenditure is projected to reach $344 billion in 2023, indicating a modest growth of 2.8% compared to the previous year. Therefore, the rise in healthcare expenditures is a significant factor driving the growth of the albumin excipient market.

Leading companies in the albumin excipient market are increasingly adopting a strategic partnership approach to support the biotechnology and pharmaceutical sectors. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology firm, partnered with Basic Pharma, a pharmaceutical company based in the Netherlands, to enhance recombinant protein production. Through this collaboration, they aim to optimize the supply chain and reduce the time-to-market for new products in the pharmaceutical sector.

Major companies in the albumin excipient market are also engaging in collaborations to foster new relationships and jointly develop innovative medicines. In June 2023, Albumedix Ltd., a UK-based pharmaceutical company, expanded its collaboration with Valneva SE to include Valneva's newly approved inactivated COVID-19 vaccine, VLA2001. This collaboration aims to address significant unmet medical needs, with Albumedix's rHA making a substantial contribution to the vaccine's manufacturing process. Valneva SE, a France-based biotech company, specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases, including VLA2001, the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

In September 2022, Sartorius AG, a Germany-based pharmaceutical and laboratory equipment manufacturer, made a strategic acquisition by purchasing Albumedix for $503 million. This acquisition strengthens Sartorius Inc.'s cell culture media business by expanding its portfolio of bioprocess solutions. This strategic move enhances Sartorius Inc.'s capabilities and market presence in the rapidly evolving field of bioprocessing. Albumedix, a UK-based company, focuses on the development and manufacturing of recombinant human albumin products, contributing to the advancement of biopharmaceuticals.

Major companies operating in the albumin excipient market include Albumin Therapeutics LLC, Biotest AG, CSL Behring,Grifols S.A., HiMedia Laboratories LLC, InVitria Inc., Medxbio Pte Ltd., Octapharma AG, RayBiotech Inc., SeraCare Life Sciences Inc., Sigma-Aldrich Pty. Ltd., Hualan Biological Engineering Inc., Kedrion Biopharma, LFB USA Inc., Shanghai RAAS Blood Products Co. Ltd., Baxter International Inc., Merck KGaA, Thermo Fisher Scientific Inc., Albumedix A/S, Bio Products Laboratory Ltd., Shire Plc., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Biopharma, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc.

North America was the largest region in the Albumin Excipient market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in the albumin excipient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albumin excipient market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Albumin excipient refers to a protein derived from blood, serving as an inactive ingredient in pharmaceutical formulations. As an excipient, it functions as a carrier or stabilizer for the active pharmaceutical ingredient.

The primary product types of albumin excipients include human serum albumin and recombinant albumin. Human serum albumin, the principal protein synthesized by the liver and found in human plasma, is a key component. These albumin excipients find applications across various end-users, including the pharmaceutical and biotechnology industry, research institutes, and other related fields.

The albumin excipient market research report is one of a series of new reports that provides albumin excipient market statistics, including albumin excipient industry global market size, regional shares, competitors with an albumin excipient market share, detailed albumin excipient market segments, market trends and opportunities, and any further data you may need to thrive in the albumin excipient industry. This albumin excipient market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The albumin excipient market consists of sales of ovalbumin, and bovine serum albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.